Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.76 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PDE7A | Q13946 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4028265 | 0.80 | PDE7A (0.72) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL27581742 | 0.79 | PDE7A (0.75) | KMT2AMAPTHTTLMNASMN1; SMN2 | |
| SCHEMBL27581731 | 0.79 | PDE7A (0.67) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL6973656 | 0.78 | PDE7A (0.60) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL7607910 | 0.78 | PDE7A (0.78) | KMT2AMAPTTDP1HTTLMNA | |
| SCHEMBL4034456 | 0.78 | KMT2A (0.53) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL4032090 | 0.76 | PDE7A (1.00) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL14685849 | 0.76 | MEN1 (0.53) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL8308443 | 0.76 | PDE7A (0.63) | MEN1KMT2AMAPTNPSR1TDP1 | |
| SCHEMBL9447037 | 0.75 | KMT2A (1.00) | MEN1KMT2AMAPTNPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| CN-100343238-C | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| CN-1585754-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-23 | — | — | CN | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | MEN1 1212/4885KMT2A 1693/4885MAPT 4300/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | MEN1 2352/4885KMT2A 1786/4885MAPT 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.